As per the report published by Fior Markets, the global bio pharma buffer market is expected to grow from USD 553.51 Million in 2017 to USD 980.78 Million by 2025, at a CAGR of 7.41% during the forecast period from 2018-2025.East and Africa. North America region emerged as the leader in the global market for the bio pharma buffer with a 41.34% share of market revenue in 2017. However Asia Pacific region is expected to grow at an increased CAGR of 9.53% over the forecast period.

“Bio Pharma Buffer Market by Type(Phosphates, Acetates, TRIS, Others), Application, Regions”,and Global Forecast 2018-2025.


Key players in the global bio pharmabuffer market areAvantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL.Biopharm International, among others. Lately Merck Pharmaceuticals has emerged as the one of the leading producers of the bio pharma buffers. Merck has a wide range of product offering under its EMPROVE® bio range. All the products under this range are manufactured to GMP, and have low bioburden and endotoxin levels as well as low UV-absorbance of aqueous solutions.

Type segment is divided into phosphates, acetates, TRIS and others. Phosphate buffer solution is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. It is extensively used in the fields of biological research. Whereas TRIS buffer solutions are used to dilute substances used in laboratory experiments due to their isotonic and non-toxic properties.Application segment is divided into research institutions, pharmaceutical industry and other. The pharmaceutical industry application segment emerged as the leader in the global bio pharma buffer market with a 53.19% share of revenue in 2017. Factors such as increasing demand for the biopharmaceuticals like vaccines, antibodies, hormones have proved to be the driving factors behind this increased market share.


Even though the rising demand for blood and blood plasma for transfusion purposes and ongoing vaccination program against polio, rubella and other such diseases around the world are driving the global bio-pharma buffer market. Factors such as the highly competitive nature of the market as well as concerns related to toxicity of certain buffer solutions are anticipated to hamper the growth of the market over the forecast period.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.